穿皮电针点刺激与甲托克洛普拉米德治疗中度至严重的术后恶心和吐:一项随机临床试验
Dong-Yu Zheng1, Peng Ding2, Ming Gong1
1Department of Anesthesiology, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai, China.
JAMA surgery
|January 28, 2026
概括
可穿戴的穿皮电针点刺激 (TEAS) 有效地控制了手术后的恶心和吐 (PONV),表现优于metoclopramide. 这种非药理学方法为增强麻醉后恢复提供了一个有希望的替代方案.
科学领域:
- 麻醉学和外科手术期间的医学.
- 整合和补充医学是整合和补充医学.
- 手术患者的康复手术患者的康复
背景情况:
- 中度至重度的术后恶心和吐 (PONV) 是一种常见的并发症,严重影响患者的康复.
- 目前对PONV的药理疗法往往无法提供足够的治疗,并且可能会产生副作用.
研究的目的:
- 评估一种针对PC6 (Neiguan) 针点的新型穿戴式穿皮电针点刺激 (TEAS) 装置的临床疗效,用于管理中度至严重的PONV.
- 为了比较TEAS与标准药理干预 (美托克洛普拉米德) 的有效性.
主要方法:
- 一个随机的,双人形,患者和观察者盲目的,主动控制的试验,涉及232名女性患者 (25-55岁) 接受甲状腺切除术或前宫手术.
- 参与者通过腕带或静脉注射美托克洛普拉米德 (10毫克) 接受了活性TEAS.
- 主要结局是2小时PONV缓解率 (数值评分表 (NRS) ≤3).
主要成果:
- 与对照组相比,TEAS组的2小时PONV缓解率 (77.6%) 显著高于对照组 (55.2%) (P < .001).
- 在24小时内复发率在TEAS组 (12.2%) 与对照组 (56.3%) 相比明显较低 (P < .001).
- 在TEAS组中没有报告任何不良事件.
结论:
- 可穿戴的TEAS是一种高效的非药物干预,用于中度至重度的PONV.
- 在PONV管理中,TEAS的疗效优于甲托克洛普拉米德.
- 这项技术提供了一种安全有效的替代方案,以改善麻醉后的康复.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
779
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
779
Clinical Trials
10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview
4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
656
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
656
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
870
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
870
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
616
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
616


